Abstract: Endothelin-1 (ET-1), a vasoactive peptide, is believed to contribute to the pathogenesis of vascular abnormalities such as hypertension, atherosclerosis, hypertrophy and restenosis. ET-1 elicits its biological effects through the activation of two receptor subtypes, ET-A and ET-B that belong to a large family of transmembrane guanine nucleotide-binding protein-coupled receptors (GPCRs). ET-1 receptor activation results in the stimulation of several signaling pathways including mitogen-activated protein kinases (MAPKs), phosphatidylinositol 3-kinase (PI3-K) and protein kinase B (PKB). An intermediary role of Ca 2+ /calmodulin-dependent protein kinases (CaMK), protein kinase C (PKC) as well as receptor and non-receptor protein tyrosine kinases in triggering the activation of MAPK and PI3-K/PKB signaling in response to ET-1 has been suggested. Activation of these pathways by ET-1 is intimately linked with the regulation of cellular hypertrophy, growth, proliferation and cell survival.
INTRODUCTION
Endothelin (ET) is a potent vasoconstrictor, that also exhibits inotropic and mitogenic properties, influences salt and water homeostasis and stimulates the renin-angiotensinaldosterone as well as sympathetic nervous system [1] [2] [3] . ET is believed to play an important role in vascular remodelling associated with experimental and human hypertension [3;4] . Increased vascular smooth muscle cell (VSMC) hypertrophy, migration and proliferation are among the key events that contribute to remodeling of the vasculature associated with cardiovascular diseases. There has been an intense interest in understanding the molecular mechanisms responsible for mediating these cellular processes. ET-1 has been shown to activate several signal transduction pathways linked to cellular hypertrophy, growth, migration and proliferation in several cell types including cardiac tissues and in cardiomyocytes [5;6] as well as in kidney mesangial cells [7] , and more recently in the vascular system [8] .
Therefore, the ET-1 system contributes to the pathogenesis of vascular disease by activating signalling pathways that are capable of modifying hypertrophic and proliferative responses.
This article provides an overview of the ET system and discusses some key signal transduction pathways that it induces in VSMC. 
STUCTURE OF ENDOTHELINS (ET)
ET is a 21 amino acid peptide which exists in at least three isoforms, ET-1, ET-2 and ET-3 [9] . All ET isopeptides share a common structure, two disulfide bonds (Cys 1 -Cys 15 and Cys 3 -Cys 11 ), a cluster of three polar charged side chains on amino acid residues 8-10 and a hydrophobic C-terminus (residues 16-21) containing the aromatic indole side chain at Trp 21 ( Fig. (1) ). ET-2 contains two amino acid substitutions (Trp 6 -Leu 7 ) and shares 90% sequence homology with ET-1. ET-3 contains six amino acid substitutions (Thr 2 , Phe 4 -Thr 5 -Tyr 6 -Lys 7 and Tyr 14 ) and shares 71 % sequence homology with ET-1 and ET-2. The hydrophobic C-terminus of ET is essential for its bioactivity, as well as the loop configuration [10] . Among the three ETs, ET-1 is the most important isopeptide in the vasculature; therefore this review will primarily focus on ET-1.
Endothelial cells are the major sites of generation of ET-1 [9] , which tightly correlates with the high expression levels of mRNA for pre-proendothelin-1 and the presence of intracellular converting enzyme responsible for generating active ET-1 in these cells [11] . Human aortic VSMCs express mRNA for ET-1, but its production is 100 fold less than that in endothelial cells. Also, ET-1 is produced by heart, kidney, posterior pituitary and the central nervous system, albeit in extremely low concentration [12] . The plasma concentration of ET-1 is in the range of 1-10 pmol/L in healthy subjects [13] , and under normal physiological conditions ETs are not circulating hormones; rather they act as autocrine and paracrine factors at multiple sites in the body [14] .
Endothelin-1 Receptors
ET-1 exerts its biological actions through the activation of two receptor subtypes, ET-A and ET-B [15, 16] . Both receptors belong to a large family of transmembrane guanine nucleotide-binding protein-coupled receptors (GPCRs). They contain seven transmembrane domains of 22-26 hydrophobic amino acids in their ∼400-aminoacid sequences with an Nterminal extracellular region and C-terminal intracellular region [15] [16] [17] . ET-A receptors are highly expressed in VSMC but are also found in cardiomyocytes, fibroblasts, hepatocytes, adipocytes, osteoblasts and brain neurons [15;18] and exhibit higher affinities for ET-1 and ET-2 than for ET-3 [15] . ET-B receptors exist predominantly in endothelial cells and smooth muscle cells, but are also found in cardiomyocytes, hepatocytes, fibroblasts, osteoblasts, different epithelial cells and neurons and have equal subnanomolar affinities for all ET iso-peptides [16] . Therefore, ET-1 binding to ET-A and ET-B receptors on smooth muscle produces vasoconstriction, cell growth and cell adhesion [19] . The binding of ET-1 to endothelial ET-B receptors stimulates the release of nitric oxide and prostacyclin which prevents apoptosis, inhibits ET converting enzyme-1 (ECE-1) expression in endothelial cells and plays an important role in ET-1 clearance [20, 21] .
ACTIVATION OF THE PHOPHOINOSITIDE CAS-CADE BY ET-1
The binding of ET-1 to its receptor activates heterotrimeric guanine nucleotide binding (G) proteins such as Gq which is the best characterized signal transducer for ET-A receptor. As with all heterotrimeric G-proteins, Gq consists of an α-subunit (αq, or related α-subunit, such as α11), a member of the β-subunit family as well as a member of the γ-subunit family and is associated with the membrane [17, 22] . In the inactive Gq heterotrimer, αq is ligated to guanosine diphosphate (GDP) and exchange of GDP for guanosine triphosphate (GTP) on αq leads to the dissociation of αq(GTP) and β γ and both remain associated with the membrane [17] . Their dissociation leads to activation of phosphoinositide-specific phospholipase Cβ (PLCβ) [23, 24] , which then hydrolyzes the membrane phospholipid, phosphatidylinositol-4',5'-bisphosphate [PtdIns(4,5)P 2 ] to two second messengers: hydrophobic diacylglycerol (DAG), which remains in the membrane, and soluble inositol-1',4',5'-trisphosphate [Ins(1,4,5)P 3 ] [23, 24] . Ins(1,4,5)P 3 diffuses into the cytoplasm and activates calcium channels of the sarcoplasmic reticulum, which leads to an increase in Ca 2+ levels in the sarcoplasm and cell contraction. DAG together with Ca 2+ activates the phosphatidylserine-dependent protein kinase, protein kinase C (PKC) (Fig. (2) ). The PKC family of serine/threonine kinases have been subdivided into three groups: the classical or conventional PKCs which require DAG and Ca 2+ include the isoenzymes α, β and γ [25] , novel PKC (nPKC) which are DAG-dependent, but Ca 2+ -independent, include the isoenzymes δ, ε, η, θ, µ and ν [25, 26] and atypical PKC (aPKC), which are independent of DAG and Ca 2+ and include ζ and λ isoenzymes [25, 27] . ET-1 has been shown to activate PKC in cardiomyocytes [28] and in other cells [29, 30] , but a direct activation of PKC by ET-1 in VSMC has not been studied in detail. Many studies have implicated PKC in the deleterious vascular effects of a variety of pathologies including diabetes and hypertension [31] . PKC has been shown to be involved in ET-1-induced signalling in VSMCs [32, 33] . Moreover, growing evidence suggests that PKC activity modulates proliferation [33;34] and contraction of VSMCs evoked by ET-1 [35] . PKC is also implicated in ET-1-induced ERK1/2 activation in rat myometrial cells [29] and in VSMCs through Ca 2+ /calmodulin-dependent protein kinases and receptor and nonreceptor protein tyrosine kinases (Fig. (2) ) [36] . Thus, ET-1-induced activation of PKC and its downstream effects appear to be important in regulating vascular functions.
ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) CASCADE BY ET-1
Another key signaling event evoked by ET-1 receptor activation consists of the MAP Kinase cascade (Fig. (2) ). The first component of this cascade is Ras, a member of the small GTP-binding protein family. Ras cycles between an active GTP-bound conformation and an inactive GDP bound form [37] . Once activated, Ras, bound to membrane, recruits Raf, also known as mitogen activated protein kinase kinase kinase MAPKKK [38] . Raf phosphorylates MEK or MAPKK at specific serine/threonine residues, which in turn, phosphorylates MAPKs, such as extracellular signal regulated kinases 1 and 2 (ERK1/2) on threonine and tyrosine residues [39] . MAPKs are serine/threonine protein kinases, which are activated in response to a variety of external stimuli such as growth factors, hormones and stress [40] [41] [42] [43] [44] [45] . Several reports have demonstrated that ET-1 activates ERK1/2 signaling pathway in many cell types including cardiomyocytes [5] , fibroblasts [46] , glomerular mesangial cells [47] and VSMCs [8] . ERK1/2, p 38mapk and c-Jun N-terminal kinases (JNK) are the principal MAPKs [48, 49] . MEK1/2 phosphorylate ERK1/2, which promote growth signaling, whereas, MEK 4/7 and MEK 3/6 phosphorylate JNK and p 38mapk respectively, which control survival, differentiation and inflammation [21, 42, 49, 50] . Several studies have suggested that the activation of MAPKs in response to ET-1 was responsible to promote proliferation in VSMC [8, 51] . It has been demonstrated that ERK5, a new member of the MAPK family, which is involved in cell differentiation and cell cycle, is activated by ET-1 and angiotensin II (AII), another vasoactive peptide with similar effects as ET-1, in VSMCs [52] . A role of MAPKs activation in regulating the contraction of VSMCs in response to ET-1 and AII has also been reported [53] [54] [55] .
Activation of ERK1/2 leads to the phosphorylation of downstream cytosolic regulatory proteins, such as p90 rsk which phosphorylates ribosomal proteins and participates in protein synthesis [56] . Also, ERK1/2 and other MAPK family members are translocated from the cytosol to the nucleus [49, 57] and phosphorylate many transcription factors which lead to activation of genes involved in growth and differentiation [49, 58] (Fig. (2) ). ET-1 also activates JNK and p 38mapk cascades but to a lesser degree than ERKs in cardiomyocytes [5, 59] , in VSMC [60] as well as in mesangial cells [7] . In addition to Ras, several other small G-protein families such as Rho, Rab and Ran have been shown to be stimulated by ET-1 [37] . ET-1 activates members of the Rho family in cardiomyocytes [61] and fibroblasts [62] , which are positive regulators of p 38mapk pathway [63] . The precise events that mediate ET-1 induced activation of Ras/Raf/MEK and ERK1/2 remain poorly characterized, however, there is some evidence supporting the involvement of PKC in Ras activation in many cell types including cardiomyocytes [28] and rat myometrial cells [29] . A possible role of a calciumregulated cytoplasmic proline-rich tyrosine kinase 2, Pyk2 (also known as related adhesion focal tyrosine kinase (RAFTK), focal adhesion kinase-2 (FAK-2) and cell adhesion kinase β (CAK β), calcium-dependent tyrosine kinase (CADTK)), in the activation of MAPK has been suggested in primary astrocytes [64, 65] and rat kidney mesangial cells [66] . Pyk2 is also activated by ET-1 in VSMC and may serve as an upstream regulator of MAPK cascade in VSMCs [8] . In several other cell types, Ca 2+ -and PKC-dependent Pyk2 activation [67] has been shown to link GPCRs to upstream regulators of MAPK-signaling, such as Src, Shc, Grb2, son of the sevenless (SOS) and the Ras guanosine nucleotide exchange factor [66, 68, 69] .. Previous data has shown that ET-1-induced association of Pyk2 through the binding of its autophosphorylated Tyr-402 to the SH2 (Src-homology 2) domain of c-Src leads to c-Src activation in many cell types including mesangial cells [66, 68] and cardiomyocytes [70] . Activated c-Src bound to Pyk2 might directly phosphorylate adjacent cellular proteins, such as p130Cas, which then act as docking protein to recruit its effectors able to activate JNK [71, 72] in cardiomyocytes [59] . Other studies have suggested calcium calmodulin-dependent protein kinase (CaMK) II as an upstream regulator of MAPK pathway in VSMCs through the activation of Pyk2 [73] . It thus appears that ET-1-induced activation of MAP kinase pathway may be mediated through several intermediate signalling components including Ca 2+ -dependant and -independent serine/threonine/tyrosine kinases in VSMC (Fig. (2) ).
ACTIVATION OF PHOSPHATIDYLINOSITOL-3 KINASE BY ET-1
Phosphatidylinositol-3 kinases (PI3-Ks), which are a family of both protein and lipid kinases have also emerged as an important effector of ET-1 action. PI3-K catalyzes the transfer of phosphate from ATP to the 3'position of the inositol ring of the membrane-localized phosphoinositides such as phosphatidylinositol (PtdIns), phosphatidylinositol-4-phosphate (PtdIns-4-P) and phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P 2 ) and generates PtdIns-3-P, PtdIns-3,4-P 2 and PtdIns-3,4,5-P 3 respectively. These phospholipids act as second messengers to activate several proteins kinase such as PtdIns-3,4,5-P 3 dependent protein kinase (PDK), protein kinase B ( PKB)/Akt and 70 KDa ribosomal protein S6 kinase (p70 S6K ) [74] .
PI3-Ks are divided into three classes based on their structure and mechanism of regulation [74] . Class I PI3-Ks generate PtdIns-3-P, PtdIns-3,4-P 2 , PtdIns-3,4,5-P 3 and are activated by receptor tyrosine kinases and G-protein-coupled receptors [75] . Class II PI3-Ks generate PtdIns-3-P and PtdIns-3,4-P 2 and possess a lipid binding domain, whereas, Class III PI3-Ks generate PtdIns-3-P only [75] . Class I PI3-Ks are ubiquitously expressed and represent the dominant form in cardiovascular tissues [76] . Class I PI3-Ks are subdivided further into class IA and IB, and are heterodimeric proteins consisting of a catalytic and a regulatory (accessory) subunit. The catalytic subunits of class IA-PI3-K exist in three isoform: p110α p110β and p110δ, among these, p110α has more ubiquitous distribution than p110β and p110δ. Similarly, the regulatory adaptor subunit for classIA-PI3-K also has several isoforms: p85α ,p85β and p55γ which are products of three genes and their splice variants [49] the class IA PI3-Ks are believed to be typically activated in response to tyrosine kinase coupled stimuli. In contrast to class IA PI3-K, the class IB enzyme (PI3-Kγ) consist of a catalytic subunit PI3-K (p110γ) and a regulatory subunit (p101) and are usually activated by G βγ subunits of G proteins liberated by GPCR activation [76] .
Except for rat glomerular mesangial cells where ET-1 was shown to directly increase the catalytic activity of PI3-K [28] , a direct activation of PI3-K in VSMC has not been documented. However, an involvement of PI3-K as an upstream mediator of several ET-1 induced responses has been reported. For example, a role of PI3-K in ET-1-induced Ca 2+ influx in carotid artery and in basilar artery contraction was recently shown by using wortmannin and LY 294002 specific inhibitor of PI3-K [77, 78] . In mesangial cells, ET-1 receptor activation has been shown to stimulate PI3-K phosphorylation through Ras [69] . Also, in rabbit internal carotid artery VSMCs, PI3-K appeared to be involved in ET-1-induced Pyk2 tyrosine phosphorylation [77] . Conversely, studies using AII, a vasoactive peptide with similar effects to ET-1, have suggested that Pyk2 regulates PI3-K cascade specifically via interaction of Pyk2 with p130Cas which lead to their association with PI3-K in VSMC [79] . Moreover, the recent work demonstrating that mice lacking PI3-Kγ are protected from AII-evoked smooth muscle contraction and hypertension provide further support for an important role of PI3-K signalling in vascular pathobiology [80] .
ACTIVATION OF PROTEIN KINASE B/AKT SIGNALING PATHWAY BY ET-1
Several downstream targets of PI3-K have been identified. However, the most widely studied target is PKB, also known as Akt (a product of akt proto-oncogene). PKB is a serine/threonine kinase with three identified isoforms in mammalian system: PKBα/Akt1, PKBβ/Akt2 and PKBγ/Akt3 [81] [82] [83] . They are activated by dual phosphorylation on threonine (Thr 308 ) and serine (Ser 473 ) residues [84] and contain a central catalytic kinase domain with specificity for serine or threonine residues in substrate proteins [85] . Nterminal of PKB possesses a pleckstrin homology (PH) domain that binds phospholipids generated by PI3-K activation. A short glycine-rich region that bridges the PH domain to the catalytic domain follows the PH domain. The C-terminus of PKB is hydrophobic and possesses a proline-rich domain [86] .
The lipid products of PI3-K bind with high affinity and specificity to the PH-domain of PKB with a preference of PtdIns-3,4-P 2 over PtdIns-3,4,5-P 3 [87] . This binding induces translocation of PKB to the plasma membrane where its phosphorylation on Thr308 by PDK-1 and Ser473 by a hypothetical kinase termed as PDK-2 is required for its complete activation [87] (Fig. (3) ).
ET-1 has been shown to increase PKB activation in cardiomyocytes [88] , myofibroblast [89] , human umbilical vein endothelial cells [90] and human osteoarthritis chondrocytes as well as A-10 VSMC [8] . An involvement of PKB in vascular disease was suggested from studies in which an enhanced PKB activity was associated with AII-induced hypertension in New Zealand White rats [91] . Furthermore, a role of PKB in regulating the ploidy levels and hypertrophy of VSMCs has also been suggested in a model of hypertension [92] . Several different substrates of PKB have been identified which include members of the cell survival/apoptosis cascade such as Bcl 2 associated death promoter (BAD) [86, 93] , caspase [94] and glycogen synthase kinase 3 (GSK-3) [95] , as well as key regulators of protein synthesis and cell growth such as mammalian target of rapamycin mTOR [96] (Fig (3) ). Thus, the stimulation of PI3-K/PKB signalling in response to ET-1 receptor activation has implications in regulating not only survival and death but also hypertrophic responses in VSMC.
CONCLUSIONS
In summary, ET-1 activates at least three signalling pathways in VSMC; these include PLC/DAG/IP3, MAPKs, and PI3-K/PKB pathways. As shown in Figs. 2 and 3 , many cytosolic protein kinases such as CaMK, Src, Pyk2 and other tyrosine kinases may be involved in initiating the ET-1 signaling events. The molecular events triggered by the activation of these signalling pathways play important role in regulating the cellular growth, proliferation and survival of VSMC. An aberrant activation of these signalling events might contribute to the development and progression of vascular disease. A better understanding of the precise mechanism responsible for aberrant signalling in VSMC will help in identifying new targets for the pharmacotherapy of vascular diseases. /Calmodulin (CaM)-dependant protein kinase (CaMK) activate receptor and non-receptor tyrosine kinases such as Src and Pyk2. Activation of these components can eventually contribute to the activation of class Ib PI3-Kγ. Class Ib PI3-Kγ is composed of a catalytic subunit, p110 and regulatory subunit, p101γ, and its activation leads to the production of PI(3,4,5)P 3 from PI (4,5) which results in recruitment and activation of PKB. PKB has several effectors such as glycogen synthase kinase 3 (GSK-3), Bcl 2 associated death promoter (BAD), caspases, mammalian target of rapamycin (mTOR), 70 KDa ribosomal protein S6 kinase (P 70 S6K) which regulate cell survival, protein synthesis and cell growth. mTOR phosphorylates eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) which, in basal state is complexed with eIF4E. This phosphorylation dissociates and liberates eIF4E which then binds to other translation initiation factors leading to protein synthesis. 
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